Introduction {#s1}
============

Aromatic amino acid biosynthetic pathways have long been a potential source for commercially relevant chemicals with diverse industrial applications (Tzin and Galili, [@B37]). One of the core metabolites that facilitate the production of useful intermediates in aromatic amino acid biosynthetic pathways is 3-dehydroshikimate (DHS), a key intermediate in the biosynthesis of shikimic acid (SA), muconic acid (MA), vanillin, and protocatechuate (PCA) (Li et al., [@B22]). This group of chemicals has drawn much attention for the major feedstock for food, drugs and commodity chemicals (Chen and Nielsen, [@B8]; Becker and Wittmann, [@B1]). Bio-based production of these compounds is a promising alternative to the current petrochemical-based production routes that are a cause of environment and energy concerns (Jan and Cavallaro, [@B15]). MA is easily converted into adipic acid and terephthalic acid, which find universal application in the synthesized nylons and polymer polyethylene terephthalate (PET) industries (Draths and Frost, [@B12]; Kruyer and Peralta-Yahya, [@B18]). In addition, SA is an initial precursor for the production of a well-known anti-virial compound named oseltamivir phosphate, also known as Tamiflu®.

DHS has a six-member carbon ring with two asymmetric carbons, which is difficult and costly to synthesize chemically (Richman et al., [@B32]; Nishikura-Imamura et al., [@B27]). On the other hand, DHS is a natural metabolite found in the shikimate pathway in plants, fungi, and bacteria, making its production feasible through microbial fermentation (Li et al., [@B21]). DHS biosynthesis in *E. coli* starts from glucose, via the glycolysis pathway, a central carbon metabolism ([Figure 1](#F1){ref-type="fig"}). Two intermediates, phosphoenolpyruvate (PEP) and erythrose-4-phosphate (E4P), are converted to DHS via 3-deoxy-D-arabino-heptulosonate-7-phosphate (DAHP) and dehydroquinate (DHQ) by DAHP synthase (*aroG, aroF*, and *aroH*), DHQ synthase (*aroB*), and DHQ dehydratase (*aroD*).

![Schematic overview of metabolic pathway for DHS biosynthesis in *E. coli*. Red crosses denote disrupted genes and bold blue arrows denote steps that are overexpressed. Dashed arrows represent two or more steps. G6P, glucose-6-phosphate; PEP, phosphoenolpyruvate; PYR, pyruvate; AcCoA, acetyl-coenzyme A; OAA, oxaloacetate; CIT, citrate; E4P, erythrose4-phosphate; DAHP, 3-deoxy-D-arabinoheptulosonate-7-phosphate; DHQ, 3-de-hydroquinate; DHS, 3-dehydroshikimate; SA, shikimic acid; PCA, protocatechuate; CA, catechol, MA, muconic acid. *ptsG*, glucose specific sugar: phosphoenolpyruvate phosphotransferase; *galP*, D-galactose transporter; *zwf*, glucose-6-phosphate 1-dehydrogenase; *tktA*, transketolase; *tyrR*, tyrosine dependent transcriptional regulator; *pykF*, pyruvate kinase 1; *pykA*, pyruvate kinase 2; *ppsA*, phosphoenolpyruvate synthase; *pckA*, phosphoenolpyruvate carboxykinase; *aroG*, DAHP synthase; *aroF*, DAHP synthase; *aroB*, DHQ synthase; *aroD*, DHQ dehydratase; *aroE*, shikimate dehydrogenase: *asbF*^*Eopt*^, 3-dehydroshikimate(DHS) dehydratase; *pcaG/H*, codon-optimized PCA deoxygenase; *aroY*^*Eopt*^, codon-optimized PCA decarboxylase; *catA*^*Eopt*^, codon-optimized CA 1,2 -dioxygenase.](fbioe-07-00241-g0001){#F1}

For several decades, many approaches have been applied to increase the carbon flux toward shikimate biosynthetic pathway for the production of several aromatic compounds. For example, there was an attempt to solve the feedback inhibition issue of DAHP synthase to improve the production of aromatic compounds (Pittard and Yang, [@B31]; Wang et al., [@B38]). Another strategy involved the inactivation of the PEP-consuming PTS system and use of another PEP-independent glucose uptake pathway, as PEP is an important precursor of an aromatic compound (Patnaik et al., [@B30]; Chandran et al., [@B5]; Johansson et al., [@B16]). Yet another approach was to eliminate the pyruvate kinases involved in PEP conversion to pyruvate, thereby enhancing the pathway that converts pyruvate to PEP (Patnaik et al., [@B30]; Chandran et al., [@B5]; Johansson et al., [@B16]; Meza et al., [@B26]; Rodriguez et al., [@B33]). Combinations of these strategies are typically used to improve the productivity of aromatic compounds (Yi et al., [@B40]; Wang et al., [@B38]; Rodriguez et al., [@B34]; Martínez et al., [@B25]; Lee et al., [@B19]).

Recently, we engineered a *Corynebacterum glutamicum* strain to overproduce MA from glucose, through redesign of the aromatic amino acid biosynthetic pathway (Lee et al., [@B19]). Through heterologous expression of a codon-optimized PCA decarboxylase gene cluster under a strong promoter, and deletions of several key genes involved in MA intermediate bypass routes, an optimized pathway for DHS-PCA-CA-MA was successfully constructed in *C. glutamicum*. Optimization of culture media and processes using the MA-producing *C. glutamicum* strain were performed to achieve a significantly increased titer of MA (Lee et al., [@B19]).

In this study, we generated engineered *E. coli* strains to overproduce both DHS and MA, through manipulation of several key genes involved in DHS biosynthesis and heterologous expression of codon-optimized foreign genes involved in DHS-to-MA conversion. These redesigned DHS-overproducing and MA-overproducing *E. coli* strains, grown in optimized media, produced the highest levels of both DHS and MA production in 7L fed-batch fermentations, indicating that the rational microbial cell factory design of DHS and MA biosynthesis could be an alternative way to complement petrochemical-based chemical processes.

Materials and Methods {#s2}
=====================

Bacterial Strains, Media, and Culture Conditions
------------------------------------------------

The bacterial strains and plasmids used in this study are listed in [Table 1](#T1){ref-type="table"}. *E. coli* DH5a was used as the cloning host, and *E. coli* K12 & AB2834 were used as parent strains. *E. coli* strains for genetic manipulations were grown in Luria-Bertani (LB) medium at 37 or 30°C. For DHS production in small-scale culture, a single colony was inoculated in LB medium at 30°C for 15 h, and secondary culture was inoculated with 1% (v/v) in the same medium at 30°C for 6 h. The miniature culture was grown using 1.3 mL of *E. coli* production medium (EPM) in a 24-well cell culture plate, at 220 rpm under 30°C, for 4 days. The composition of the EPM for DHS and MA production was: glucose (5 g/L), glycerol (10 g/L), yeast extract (2.5 g/L), tryptone (2.5 g/L), KH~2~PO~4~ (7.5 g/L), MgSO~4~ (0.5 g/L), (NH~4~)~2~SO~4~ (3.5 g/L), NH~4~Cl (2.7 g/L), Na~2~SO~4~ (0.7 g/L), Na~2~HPO~4~•12H~2~O (9 g/L), and a trace metal solution (1 mL/L). The trace metal solution contained FeSO~4~•7H~2~O (10 g/L), CaCl~2~•2H~2~O (2 g/L), ZnSO~4~•7H~2~O (2.2 g/L), MnSO~4~•4H~2~O (0.5 g/L), CuSO~4~•5H~2~O (1 g/L), (NH~4~)~6~Mo~7~O~24~•4H~2~O (0.1 g/L), and Na~2~B~4~O~7~•10H~2~O (0.02 g/L).

###### 

Plasmids and strains used in the study.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Strains**          **Relevant characteristics**                                                                                               **References**
  -------------------- -------------------------------------------------------------------------------------------------------------------------- ----------------
  *E. coli* AB2834     K12 *ΔaroE*                                                                                                                YALE univ.

  *E. coli* Inha24     *E. coli ΔtyrR*                                                                                                            This study

  *E. coli* Inha29     *E. coli* Inha24 *ΔptsG*                                                                                                   This study

  *E. coli* Inha52     *E. coli* Inha29 *ΔpykA*                                                                                                   This study

  *E. coli* Inha95     *E. coli* Inha52 *ΔlacI:*: P*lac_aroB_aroD\_*P*lac_ppsA_galP*                                                              This study

  *E. coli* Inha99     *E. coli* Inha52 *ΔlacI:*: P*lac_aroB\_ aroD*                                                                              This study

  *E. coli* Inha103    *E. coli* Inha52 *ΔlacI:*: P*lac_aroB_aroD\_*P*lac*\_*aroG*\_*aroF*P*lac_ppsA_galP*                                        This study

  *E. coli* InhaM101   *E. coli* Inha103/pMESK1                                                                                                   This study

  *E. coli* InhaM104   *E. coli* Inha103/pMESK4                                                                                                   This study

  *E. coli* InhaM105   *E. coli* Inha103/pMESK5                                                                                                   This study

  *E. coli* InhaM106   *E. coli* Inha103/pMESK6                                                                                                   This study

  *E. coli* InhaM107   *E. coli* Inha103/pMESK7                                                                                                   This study

  *E. coli* InhaM108   *E. coli* 4 Inha103/pMESK8                                                                                                 This study

  **Plasmids**                                                                                                                                    

  T-vector             T&A cloning vector                                                                                                         RBC\
                                                                                                                                                  Real biotech.

  pUC18                Standard backborn vector for MA expression                                                                                 Clontech

  pET21b(+)            Protein expression vector for *E. coli*                                                                                    Novagen

  pKOV                 The suicide vector containing the *Bacillus subtilis sacB* gene and temperature sensitive pSC101 replication origin        Addgene

  pKOV\_*tyrR*         pKOV containing a PCR fragment for the markerless disruption of the *tyrR* gene                                            This study

  pKOV\_*ptsG*         pKOV containing a PCR fragment for the markerless disruption of the *ptsG* gene                                            This study

  pKOV\_*pykA*         pKOV containing a PCR fragment for the markerless disruption of the *pykA* gene                                            This study

  pKOV\_*lacI*         pKOV containing a PCR fragment for the markerless disruption of the *lacI* gene                                            This study

  pKOV_BD              pKOV\_*lacI* derivative for P*lac_aroB_aroD* integration into *lacI* region                                                This study

  pKOV_PABD            pKOV\_*lacI* derivative for P*lac*\_*ppsA_galP*\_P*lac*\_*aroB_aroD* integration into *lacI* region                        This study

  pKOV_PAGFBD          pKOV\_*lacI* derivative for P*lac*\_*ppsA_galP*\_P*lac*\_*aroG_aroF*\_P*lac*\_*aroB_aroD* integration into *lacI* region   This study

  pMESK1               pUC18 modification vector including Lac promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                                This study

  pMESK4               pUC18 modification vector including *oppA* promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                             This study

  pMESK5               pUC18 modification vector including *dps* promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                              This study

  pMESK6               pUC18 modification vector including *rmf* promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                              This study

  pMESK7               pUC18 modification vector including *fusA* promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                             This study

  pMESK8               pUC18 modification vector including *rnpB* promoter *asbF^*Eopt*^- aroY^*Eopt*^- catA^*Eopt*^*                             This study
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------

Construction of Plasmids and Strains
------------------------------------

All constructed plasmids for integration and disruption are listed in [Table 1](#T1){ref-type="table"}. Plasmid DNA extraction and purification were performed using a commercial kit (TIANGEN). For PCR, the Pfu DNA polymerase and HIFI DNA polymerase (TransGen) were used. For disruption and substitution of chromosomal genes, suicide vector pKOV (Addgene, USA) was used, which has the *sacB* gene for providing a markerless system. The constructed plasmids were transformed into *E. coli* AB2834 by electroporation.

For disruption of *tyrR, ptsG, pykA*, and *lacI* genes, homologous DNA fragments were PCR-amplified with primer sets R1-R4, G1-G4, A1-A4, and I1-I4, respectively, which were then inserted into the pKOV vector, generating pKOV-R, pKOV-G, pKOV-A, and pKOV-I, respectively. For overexpression of several genes, T-lac was generated by inserting the lac promoter and RBS into T-vector. The lac promoter and RBS were amplified with primer sets Plac1-Plac2 and RBS1-RBS2 from pUC18 and the pET-21b(+) vector. DNA fragments containing *E. coli aroB, aroD, galP, ppsA, aroG*, and *aroF* genes were amplified with primer sets B1-B2, D1-D2, P1-P2, A3-A4, G3-G4, and F1-F2, respectively, and the amplified DNA fragments were inserted into the T-lac vector, generating T-BD, T-PA, and T-GF. Subsequently, Plac\_*aroB_aroD* cassette was amplified with primer sets BD1-BD2 and T-BD as a template, and the amplified cassette was inserted into pKOV-I, generating pKOV-BD. The Plac\_*aroB_aroD* and Plac\_*galP_ppsA* cassettes were amplified with primer sets BD1-BD3 and PA1-PA2, using T-BD and T-PA as a template, respectively, and the amplified cassettes were inserted into pKOV-I, generating pKOV-PABD. The Plac\_*aroG_aroF* cassette was amplified with primer sets GF1-GF2, using T-GF as a template, and the amplified cassette was inserted into pKOV-PABD, generating pKOV-PAGFBD ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

A series of *E. coli* DHS-producing strains were constructed using the host strain AB2834, which was constructed by the markerless disruption of the *aroE* gene. The *tyrR* gene in AB2834 was disrupted using plasmid pKOV-R, generating the Inha 24 strain. Subsequently, the *ptsG* and *pykA* genes were disrupted from Inha 24 using plasmids pKOV-G and pKOV-A, generating strains Inha 29 and Inha 52, respectively. Markerless integration of *aroB* and *aroD* genes, under the control of the *lac* promoter, were integrated at *LacI* gene locus into strain Inha 52 using plasmid pKOV-BD, generating the strain Inha 99 ([Figure 2A](#F2){ref-type="fig"}). Using the plasmid pKOV-PABD, the *aroB, aroD, ppsA*, and *galP* genes, under the control of the lac promoter, were integrated into strain Inha 52, generating strain Inha 95. The *aroB, aroD, ppsA, galP, aroG*, and *aroF* genes, under the control of the lac promoter, were chromosome-integrated using plasmid pKOV-PAGFBD in Inha 52 strain, generating strain Inha 103.

![**(A)** Construction of *E. coli* mutants for overproduction of DHS. **(B)** HPLC analysis of DHS production yields in DHS-producing *E. coli* strains. *E. coli* cells were cultured in 1.3 mL of EPM at 30°C for 96 h. Data represent averages and standard deviations from two independent experiments.](fbioe-07-00241-g0002){#F2}

RNA Sequencing
--------------

For RNA sequencing, *E. coli* strains AB2834 and Inha52 were cultured in LB media for seeding, and in 500 mL of EPM media for the main production. Growth curves were generated, and each strain was sampled at the early stage of exponential phase (AB2834, 4 h; Inha52, 7 h) as well as the early stage of stationary phase (AB2834, 9 h; Inha52, 12 h). RNeasy mini prep kit (Qiagen, CA) was used for total RNA isolation, according to the manufacturer\'s instructions. DNaseI (TaKaRa, Japan) was used to eliminate any potential chromosomal DNA contamination. RNA-Seq was performed by ChunLab Inc., Korea.

Metabolite Analysis
-------------------

The *E. coli* cells were removed from cultures by centrifugation and culture supernatant was filtered using a membrane filter. The metabolites were separated by HPLC using an Aminex HPX-87H column (Bio-rad, Japan). The mobile phase was 2.5 mM H~2~SO~4~, and a flow rate of 0.6 mL/min was used for metabolites. The column had to be heated at a temperature of 65°C for detection of metabolites. MA and DHS were analyzed at wavelengths of 262 and 236 nm, respectively. Organic acids, including succinic acid, acetic acid, formic acid, and lactic acid, were detected at wavelengths of 210 nm.

Fed-Batch Fermentation
----------------------

The first growth culture was carried out in a conical tube containing 5 mL of LBG medium (30°C and 200 rpm). After 12 h of culture, 0.2 mL of the culture broth was inoculated in a 250-mL baffled flask containing 20 mL of culture medium, and cultured at 30°C and 200 rpm in an incubator. After 6 h, the second culture broth was inoculated into a 7-L fermenter (1% v/v inoculum). Production culture was carried out using the PB4-md5 medium in a 7-L fermenter (working volume: 2 L). The PB4-md5 medium includes: 30 g/L glucose, 10 g/L glycerol, 15.75 g/L yeast extract, 21.375 g/L tryptone, 5.25 g/L KH~2~PO~4~, 1 g/L MgSO~4~ · 7H~2~O, 0.8 g/L citric acid, 1 mL/L trace metals, and 200 μg/L thiamine hydrochloride. The feeding medium includes: 600 g/L glucose, 100 g/L yeast extract, 20 g/L MgSO~4~ · 7H~2~O, and 5 mL/L trace metal. Phosphate was not added to the feeding medium, to allow for the regulation of cell growth. The pH levels were 7.0 in each culture (10N NaOH, 3M HCl), and the DO level was maintained above at 30% by controlling the agitation, aeration, and feeding rates. The configuration of the fermenter was as follows: two impellers with turbine and marine impeller, ring-type sparger with 12 holes, top-driven, and 160 mm tank diameter. The feeding medium was supplied when glucose was depleted, using a peristaltic pump.

Construction of a Gene Cassette Involved in DHS-to-MA Conversion
----------------------------------------------------------------

*E. coli* Inha M101 was prepared by transformation of a plasmid pMESK1 into Inha M103. pMESK1 was prepared by ligation of an *AsbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ cassette to pUC18. Codon-optimized gene versions for increased protein expression in *E. coli* were synthesized from Cosmo Genetech, Korea. Digestion of pUC57_M1 with *Xba*I and *Hind*III liberated a 3.3-kb *asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ fragment. Plasmid pUC18 was digested at the same restriction site. Subsequent ligation of *asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ to pUC18 resulted in pMESK1. The ligation of *the asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ cassette was verified by restriction enzyme digestion analysis. To select the promoter for expression of heterologous gene cluster, the intergenic region of *rnpB, fusA, oppA, dps*, and *rmf* genes (upstream region of the start codon) was amplified by PCR and cloned into pMESK1 digested by *Eco*RI and *Xba*I.

Results {#s3}
=======

Redesign of 3-Dehydroshikimate Biosynthetic Pathway in *Escherichia coli*
-------------------------------------------------------------------------

We used the *E. coli* AB2834 strain as a parental host for DHS accumulation, which is an *aroE* mutant strain lacking shikimate dehydrogenase (Draths and Frost, [@B12]). To further improve DHS accumulation, we first disrupted the key genes involved in DHS accumulation in *E. coli* AB2834. The *tyrR* repressor, which exerts negative control on the transcription of *aroG* and *aroF* genes with two aromatic amino acids (L-phenylalanine and L-tyrosine), was disrupted (Bongaerts et al., [@B4]). The *tyrR*-disruption mutant strain (named Inha 24) accumulated 4.92 g/L of DHS in the culture medium after 96 h, whereas the parental strain produced 3.54 g/L of DHS under the same culture condition. Next, the *ptsG* gene, one of the phosphotransferase system genes that consume PEP for glucose uptake, was disrupted in the Inha 24 strain (named Inha 29) to increase the availability of PEP, a DHS precursor. The Inha 29 strain produced 5.82 g/L of DHS under the same culture condition. Finally, the *pykA* gene, encoding a pyruvate kinase, was also disrupted in the Inha 29 strain (named Inha 52), leading to a production of 7.72 g/L of DHS, signifying a more than 2-fold improvement in production yield relative to the parental strain ([Figure 2B](#F2){ref-type="fig"}).

RNA sequencing-based comparative transcriptome analysis between the parental strain and Inha52 revealed that the transcription levels of the DHS biosynthetic pathway genes such as *aroB* (encoding DHQ synthease) and *aroD* (encoding DHQ dehydratase) were significantly reduced in the Inha52 strain (data not shown). To overcome this limitation, both *aroB* and *aroD* genes were overexpressed under the control of the *lac* promoter via an integration plasmid pKOV-BD, generating the strain Inha 99 ([Figure 2A](#F2){ref-type="fig"}). The Inha 99 strain, harboring an extra copy of *aroB* and *aroD* genes, produced 8.06 g/L of DHS ([Figure 2B](#F2){ref-type="fig"}). In addition, Inha 95 was constructed using pKOV-PABD to overexpress the *galP* and *ppsA* genes as well as *aroB* and *aroD* genes in the Inha 52 strain ([Figure 2A](#F2){ref-type="fig"}). The *galP* gene, encoding D-galactose transporter, was overexpressed to improve the level of glucose uptake. The *ppsA* gene, encoding a phosphoenolpyruvate synthase, was also overexpressed to increase the availability of PEP. Inha 95, overexpressing the *aroB, aroD, galP*, and *ppsA* genes, produced 9.20 g/L of DHS ([Figure 2B](#F2){ref-type="fig"}). Subsequently, *aroG* and *aroF* genes, encoding DAHP synthase, were additionally overexpressed in strain Inha 95, generating the Inha 103 strain ([Figure 2A](#F2){ref-type="fig"}). The Inha 103 strain, harboring extra copies of *aroB, aroD, galP, ppsA, aroG*, and *aroF* genes under the control of the *lac* promoter, produced 9.28 g/L of DHS, which is 20% higher DHS yield than that of strain Inha 52, and 2.6-fold higher than that of the parental strain ([Figure 2B](#F2){ref-type="fig"}; [Supplementary Table 2](#SM1){ref-type="supplementary-material"}). Thus, the DHS production yield of our recombinant strains increased gradually through serial disruptions and overexpression of the genes involved in DHS synthesis.

Fed-Batch Fermentation for DHS Production
-----------------------------------------

During the statistical medium optimization process in shake-flask cultures using the metabolically engineered *E. coli* cells, composition of the production medium was found to be a very important factor for enhanced DHS production. Sufficient supply of dissolved oxygen during the entire fermentation period was also observed to be crucial, as revealed by higher DHS production yield according to increase in oxygen mass transfer rate (kLa) through increment of agitation speed (rpm). Therefore, we intended to develop a fed-batch operation process that could efficiently control the producers\' fermentation physiology, simultaneously overcoming the oxygen-limited culture conditions caused by high cell density in bioreactor fermentations. The fed-batch culture was carried out using the abovementioned four strains, i.e., Inha 24, Inha 29, Inha 52, and Inha 103. The optimized medium from flask culture was again optimized for the C/N ratio in the fermenter. The DHS production yield was confirmed by fed-batch culture based on this medium. Scaled-up operations from shake flasks to fermenters are largely affected by the operating conditions such as gas-liquid mass transfer, shear stress, mixing time, antifoam, pH regulation, and power input. A phosphate-limited fed-batch culture was performed to regulate cell growth. After the glucose level were almost depleted in the fermentation broth, feeding medium was continuously injected using a peristaltic pump to maintain below 10 g/L to prevent the production of organic acids by residual glucose. As shown in [Figure 3](#F3){ref-type="fig"}, DO levels could be successfully maintained above 30% during the whole fermentation time in the respective fed-batch fermentation, thereby leading to overcoming the undesirable oxygen-limited conditions due to relatively high cell density. It is well-known that when *E. coli* cells become oxygen-limited, cellular metabolism rapidly changes, producing proteases that can degrade foreign proteins, thus lowering the production ability of the transformed *E. coli* cells.

![Time-course profiles of cell growth (DCW), glucose, organic acid, and metabolite production by strains in the 7-L fermenter. **(A)** Inha 24: The feeding medium was sequentially injected at culture periods of 17, 19, 24, 27, 42, 47, and 54 h, at a rate of 0.1176, 0.1568, 0.1176, 0.1568, 0.0784, 0.0522, and 0.1176 mL/min, respectively. **(B)** Inha 29: The feeding medium was sequentially injected at culture periods of 17, 19, 24, 42, 47, 54, and 89 h, at a rate of 0.0392, 0.1176, 0.1568, 0.0784, 0.0522, 0.1176, and 0.0784 mL/min, respectively. **(C)** Inha 52: The feeding medium was sequentially injected at culture periods of 17, 19, 42, 47, 54, 65, and 89 h, at a rate of 0.0392, 0.1176, 0.0784, 0.0522, 0.1568, 0.1176, and 0.0522 mL/min, respectively. **(D)** Inha 103: The feeding medium was sequentially injected at culture periods of 18, 24, 42, and 66 h at a rate of 0.1306, 0.1568, 0.1306, and 0.1045 mL/min, respectively.](fbioe-07-00241-g0003){#F3}

All four strains consumed glucose for 17 h and started feeding from this time onwards. As a result, in the Inha 24 strain, the cells showed steady growth, and the DCW (Dry cell weight) and production yield declined 48 h after the incubation; the DCW was about 42 g/L and the DHS was about 45 g/L. In the same culture condition, the Inha 29 strain exhibited the maximum cell dry weight of about 37 g/L and a DHS level of 74 g/L. In the Inha 52 strain, DCW was lower than that of the Inha 29 strain, but DHS production yield was as high as 81 g/L, implying that there is a competitive relationship between cell growth and DHS production. Although DHS is a primary metabolite, its production in the engineered strains exhibited typical secondary metabolite patterns ([Figure 3](#F3){ref-type="fig"}). In aromatic amino acid processes, *E. coli* and *C. glutamicum* have characteristic metabolites that suppress cell density at certain concentrations (Cheng et al., [@B9]; Rodriguez et al., [@B34]; Lee et al., [@B19]). Finally, in the Inha 103 strain with enhanced flux to DHS, the DCW was about 35 g/L, slightly lower than that of Inha 52, while the production yield of DHS had increased by 44% to 117 g/L. The specific production yield (Yp/x) was 1.07 g DHS/g DCW for the Inha 24 strain, 2 g DHS/g DCW for the Inha 29 strain, 2.25 g DHS/g DCW for the Inha 52 strain, and 3.34 g DHS/g DCW for the Inha 103 strain. The specific production yield of the Inha 103 strain was 3.1-times higher than that of Inha 24 ([Table 2](#T2){ref-type="table"}; [Supplementary Figure 3](#SM1){ref-type="supplementary-material"}).

###### 

A, 7-L lab-scale fermentation; B, 50-L pilot-scale fermentation; *P*~*f*~, maximum DHS production (g IA/L); *X*~*f*~, maximum dry cell weight (g DCW/L); *S*~*f*~, final residual glucose concentration (g glucose/L); *Q*~*p*~, average volumetric DHS production rate (g DHS/L/h); *q*~*p*~, average specific DHS production rate (g DHS/g DCW/h); *Y*~*p*/*x*~, specific DHS production (g DHS/g DCW); *Y*~*p*/*s*~, DHS production yield based on glucose (g DHS/g glucose); *Y*~*x*/*s*~, DCW yield based on glucose (g DCW/g glucose).

             ***P~***f***~***   ***X~***f***~***   ***S~***f***~***   ***Q~***p***~***   ***q~***p***~***   ***Y~***p*/*x***~***   ***Y~***p*/*s***~***   ***Y~***x*/*s***~***
  ---------- ------------------ ------------------ ------------------ ------------------ ------------------ ---------------------- ---------------------- ----------------------
  Inha 24    45                 42                 2                  0.375              0.009              1.07                   0.21                   0.19
  Inha 29    74                 37                 2                  0.616              0.017              2.0                    0.27                   0.14
  Inha 52    81                 36                 5                  0.675              0.019              2.25                   0.34                   0.15
  Inha 103   117                35                 2                  0.975              0.028              3.34                   0.39                   0.12

Heterologous Expression of the Genes Involved in DHS-to-MA Conversion
---------------------------------------------------------------------

We tried to produce muconic acid, another valuable compound, through heterologous expression of the genes involved in DHS-to-MA conversion in the DHS-overproducing *E. coli* strain. Previously, three foreign genes (*aroZ, aroY*, and *catA*) were reported to be responsible for the DHS-to-MA conversion in *E. coli* (Draths and Frost, [@B12], [Figure 1](#F1){ref-type="fig"}). Similarly, we generated a codon-optimized single operon construct containing three genes, *asbF* from *Bacillus thuringiensis* (encoding DHS dehydratase for DHS-to-PCA), *aroY* from *Klebsiella pneumoniae* (encoding PCA decarboxylase for PCA-to-CA), and *catA* from *Acinetobacter calcoaceticus* (encoding catechol 1,2-dioxygenase for CA-to-MA). Genes *asbF*^*Eopt*^*, aroY*^*Eopt*^, and *catA*^*Eopt*^ were cloned into modified pUC18 under the control of the lac promoter, thus generating pMESK1. To optimize the heterologous foreign genes expression in a DHS-overproducing *E. coli* strain, we searched for a naturally-suitable promoter *via* comparative transcriptome analysis between the parental strain and Inha 52 ([Supplementary Figure 1](#SM1){ref-type="supplementary-material"}). Among the gene expression profiles during the culture duration, five promoters were selected according to their transcription strength, and each selected promoter was cloned to control the foreign gene cassette ([Supplementary Figure 2A](#SM1){ref-type="supplementary-material"}). The *E. coli* strains expressing each promoter from pMESK4 to pMESK8 were named *E. coli* Inha M104--M108, respectively, and were tested to determine whether MA accumulated in their culture broths. The production level of MA varied, depending on the promoter, as shown in [Supplementary Figures 2B](#SM1){ref-type="supplementary-material"} and [4](#SM1){ref-type="supplementary-material"}. The highest MA titer was observed in strain Inha 103, expressing *oppA* gene promoter, which encodes periplasmic oligopeptides-binding protein in *E. coli*. It yielded up to 1,789 mg/L of MA, an 8-fold increase compared with strain Inha M101 (Plac\_ *asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^), which showed an MA titer of 223 mg/L. DHS was accumulated in relatively large amounts in two strains (P*lac* and P*dps*), and only a small amount of MA was produced in the other two strains (P*rmf* and P*rmpB*). In the 7-L fermenter, the Inha 103 strain containing the *asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ operon cassette under the control of *oppA* promoter produced 64.5 g/L MA with little accumulation of other intermediates ([Figure 4](#F4){ref-type="fig"}).

![Time-course profiles of cell growth (DCW, pink closed diamond), glucose (cyan closed diamond), organic acid, and metabolite production by the engineered *E. coli* InhaM104 in the 7-L fermenter. The feeding medium was sequentially injected at culture periods of 18, 24, and 46 h, at a rate of 0.0392, 0.0784, and 0.0653 mL/min, respectively. Closed gray square, total metabolite; red closed diamond, DHS (3-dehydroshikimic acid); green closed diamond, PCA (protocatechuate); yellow closed triangle, CA (catechol); blue closed diamond, MA (*cis-cis* muconic acid).](fbioe-07-00241-g0004){#F4}

Discussion {#s4}
==========

In general, strategies to redesign metabolic pathways constitute the primary goal of metabolic engineering, which is a prerequisite to produce certain valuable compounds. This strategy has been used to engineer the shikimate pathway for producing a number of useful aromatic products in *E. coli*. For example, Chandran et al. reported an engineered *E. coli* strain that achieved 84 g/L of shikimate with a yield of 0.33 mol/mol glucose (Chandran et al., [@B5]). In addition, Wang et al. reported a 48 g/L yield of L-tryptophan, with a conversion ratio of 21.87% from glucose (Wang et al., [@B38]). It was previously reported that the introduction of heterologous biosynthetic genes such as *aroZ, aroY*, and *catA* into the *aroE*-deleted *E. coli* led to the accumulation of MA up to 36 g/L via benzene-independent pathway (Niu et al., [@B28]). In addition, various microbial cell factory strategies were also purposed to enhance production of MA or shikimic acid ([Table 3](#T3){ref-type="table"}) (Noda and Kondo, [@B29]; Bilal et al., [@B2]).

###### 

Recent overview of engineered microbial strains for enhanced shikimate and MA biosynthesis.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Product**   **Organism/strain**            **Feedstock**        **Culture style**     **Titer**               **Fermentation duration (h)**   **References**
  ------------- ------------------------------ -------------------- --------------------- ----------------------- ------------------------------- -------------------------
  Shikimate     *Escherichia coli*             Glycerol + glucose   Batch                 1.78 g/L                36                              Bilal et al., [@B3]

  Shikimate     *E. coli*                      Glycerol             Batch                 5.33 g/L                24                              Lee et al., [@B20]

  Shikimate     *E. coli*                      Glucose              Batch and fed-batch   1.73 g/L (Batch)\       54                              Gu et al., [@B14]
                                                                                          13.15g/L (Fed batch)                                    

  Shikimate     *E. coli*                      Glycerol + glucose   Fed-batch             4.14 g/L (Batch)\       48                              Liu et al., [@B24]
                                                                                          27.41 g/L (Fed-batch)                                   

  Shikimate     *E. coli*                      Glucose              Batch                 3.12 g/L                --                              Cui et al., [@B10]

  Shikimate     *E. coli*                      Glucose              Batch and fed-batch   1.12 g/L (Batch)\       --                              Chen et al., [@B7]
                                                                                          14.6 g/L (Fed-batch)                                    

  Shikimate     *E. coli*                      Glycerol             Fed-batch             1.85 g/L                44                              Chen et al., [@B6]

  Shikimate     *Pichia stipites*              Glucose              Batch                 3.11 g/L                120                             Gao et al., [@B13]

  Shikimate     *Corynebacterium glutamicum*   Glucose              Fed-batch             141 g/L                 48                              Kogure et al., [@B17]

  MA            *E. coli*                      Glucose, xylose      Fed-batch             4.7 g/L                 72                              Zhang et al., [@B42]

  MA            *E. coli*                      Glucose, glycerol    Batch                 390 mg/L                32                              Sun et al., [@B36]

  MA            *E. coli*                      Glucose, glycerol    Batch                 1.5 g/L                 48                              Lin et al., [@B23]

  MA            *E. coli*                      Glucose              Batch                 170 mg/L                72                              Sengupta et al., [@B35]

  MA            *Saccharomyces cerevisiae*     Glucose              Batch                 1.56 mg/L               170                             Weber et al., [@B39]

  MA            *S. cerevisiae*                Glucose              Batch                 141 mg/L                108                             Curran et al., [@B11]

  DHS           *E. coli*                      Glucose              Batch                 25.48 g/L               62                              Yuan et al., [@B41]

  DHS           *E. coli*                      Glucose              Fed-batch             69g/L                   --                              Li et al., [@B21]
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------

In this study, a phosphate-limited fed-batch fermentation process was successfully developed for enhanced production of DHS using a DHS-overproducing *E. coli* strain constructed by redesigning its biosynthetic pathway. The phosphate-limited fed-batch operation in the 7 L bioreactor level was observed to strictly regulate the specific growth rate (μ) and the glucose consumption rate and suppresses the production of undesirable byproducts by effectively controlling DO levels. Notably, under this culture conditions, DHS was biosynthesized in a non-growth-associated mode during the later stage of the fed-batch operations, efficiently utilizing higher portion of the supplied nutrients into the DHS biosynthesis rather than cellular growth. As a result, the Inha 103 strain showed significantly high level of DHS production amounting to 117 g/L (at a production yield (Yp/s) of 0.39 g/g glucose) in the 7-L fed-batch bioreactor culture, \~13-fold increase as compared to the parallel flask culture (9 g/L) performed under the identical culture conditions.

It was observed that sufficient amount of dissolved oxygen (DO) should be supplied in the cultivation of the metabolically engineered *E. coli* cells for enhanced production of DHS: Increase in oxygen mass transfer rate (kLa) through increment of agitation speed (rpm), and expansion of the diameter ratio of the impeller to the fermenter vessel up to 0.46 resulted in higher productivity of DHS. In addition, as described in this paper, by installing a turbine impeller just above the ring-type sparger for efficient break-down of the sparged air, and a marine impeller above the turbine impeller for proficient mixing of the dissolved oxygen, DO levels could be successfully maintained above 50% during the whole fermentation period, thereby leading to overcoming the undesirable oxygen-limited conditions due to relatively high cell density. Notably, with almost the same configuration of this fermenter system, higher production levels of MA (muconic acid) had been observed, maintaining DO levels above 40% during the entire fermentation time, leading to facilitated transfer of DO to the producing cells, and thereby improving MA production ([Figure 4](#F4){ref-type="fig"}). In addition, by carefully controlling the composition and feeding rate of the supplied medium during the fed-batch operation, it was possible to overcome DO-limited conditions, simultaneously minimizing the production of the byproducts caused by high levels of residual glucose in the fermentation broth. Notably, under the phosphate-limited fed-batch fermentations, DHS was observed to be biosynthesized almost in a growth-associated mode, thus resulting in the remarkable enhancement in DHS productivity (i.e., \~6-fold increase as compared to the parallel batch bioreactor fermentation performed under the identical environments).

Such a remarkable production yield could be achieved by applying a combination of several metabolic engineering strategies for DHS production to *E. coli* strains. We demonstrated that engineering of key genes for DHS production using the host strain *E. coli* AB2834, in which the *aroE*-encoded shikimate dehydrogenase is inactivated, gradually increased the DHS production. We inactivated the *tyrR*-encoded tyrosine-dependent transcriptional regulator, which is a feedback repressor of *aroG*- and *aroF*-encoding DAHP synthase, for improving the transcription levels. Among the several approaches to improve PEP availability for promoting DHS production, we generated PTS-inactivated strain by disrupting *ptsG*, which is a PEP-dependent glucose transporter. Instead, we overexpressed *galP*-encoding D-galactose transporter, which is another glucose-uptake route. In addition, *pykA*-encoding pyruvate kinase 2 was removed and *ppsA*-encoded PEP synthase was overexpressed for reconversion of pyruvate to PEP. Furthermore, we overexpressed the genes on the biosynthetic pathway to complete the DHS-overproducing strain. Construction of an MA-producing *E. coli* cell factory was carried out by the introduction of a single operon containing *asbF*^*Eopt*^ *-aroY*^*Eopt*^ *-catA*^*Eopt*^ gene cluster, as well as applying a promoter engineering strategy through the transcriptome analysis. Although the current heterologous gene cluster converts MA to about 50% of DHS, strengthening and optimization of the DHS-PCA-CA-MA route in further studies could result in better performing strains with higher DHS-to-MA bioconversion efficiency.

In summary, we report the construction of *E. coli* strains capable of producing DHS at high concentrations from D-glucose. To accumulate high concentrations of DHS, *tyrR, ptsG*, and *pykA* gene were sequentially deleted from *E. coli* AB2834, in which the *aroE* gene was mutated to prevent the conversion of DHS to SA. Extra copies of *aroB, aroD, galP, ppsA, aroG*, and *aroF* genes involved in DHS biosynthesis were additionally inserted to maximize DHS accumulation. MA was also successfully produced by a heterologous expression pathway for DHS-to-MA bioconversion. A controlled fed-batch operation was performed with a statistically optimized production medium in a 7L bioreactor and the redesigned *E. coli* strain could convert DHS to MA efficiently, thereby producing about 64.5 g/L MA with almost no accumulation of metabolic intermediates such as PCA, CA, and DHS. This study demonstrates the potential value of *E. coli* host to produce high level of an intermediate metabolite of aromatic pathways and the rational cell factory design approach to possibly complement petrochemical-based chemical processes.
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